Skip to main content
. 2021 Sep 7;20:15347354211035450. doi: 10.1177/15347354211035450

Figure 6.

Figure 6.

Bax and Bcl2 protein expressions of proliferative HCT116, Sen-HCT116, and proliferative MCF7, Sen-MCF7 cells by flow cytometry. (a) Bcl2-associated X protein (Bax) protein levels of proliferative and Sen-HCT116. (b) Percentages of Bax protein levels of proliferative and Sen-HCT116. (c) B-cell lymphoma 2 (Bcl2) protein levels of proliferative and Sen-HCT116. (d) Percentages of Bcl2 protein levels of proliferative and Sen-HCT116. (e) Bax protein levels of proliferative and Sen-MCF7. (f) Percentages of Bax protein levels of proliferative and Sen-MCF7. (g) Bcl2 protein levels of proliferative and Sen-MCF7. (h) Percentages of Bcl2 protein levels of proliferative and Sen-MCF7. The data were analyzed with 1-way ANOVA (Tukey’s Multiple Comparison Test). Error bars represent mean ± SD. *P < .05, **P < .01, and ***P < .001 versus control. ++P < .01 and +++P < .001 versus Dox5. xP < .05, xxP < .01, and xxxP < .001 versus HCT116 + TQ or MCF7 + TQ. Control refers to proliferative-untreated HCT116 or -untreated MCF7. HCT116 + TQ refers to HCT116 treated with 50 µM TQ for 24 hours. MCF7 + TQ refers to HCT116 treated with 50 µM TQ for 24 hours. Dox5 refers to Sen-HCT116 or Sen-MCF7 with 100 nM Dox for 5 days. HCT116 + Dox5 + TQ refers to Sen-HCT116 with 100 nM Dox for 5 days, then treated with 50 µM TQ for 24 hours. MCF7 + Dox5 + TQ refers to Sen-MCF7 with 100 nM Dox for 5 days then treated with 50 µM TQ for 24 hours. TQ, thymoquinone. All assays were done in triplicate at least.